We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

9 hedge funds and large institutions have $377K invested in ABVC BioPharma in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.15% less ownership

Funds ownership: 1.99% → 1.85% (-0.15%)

18% less funds holding

Funds holding: 11 → 9 (-2)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

34% less capital invested

Capital invested by funds: $571K → $377K (-$194K)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
9
Holders Change
-2
Holders Change %
-18.18%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$3.16K
2
BlackRock
BlackRock
New York
+$1.88K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$273
4
Bank of America
Bank of America
North Carolina
+$37

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$13.5K
2
Citadel Advisors
Citadel Advisors
Florida
-$11K
3
Jane Street
Jane Street
New York
-$10K
4
Millennium Management
Millennium Management
New York
-$10K
5
TRCT
Tower Research Capital (TRC)
New York
-$628

ABVC Hedge Fund Activity: Q4 2022 in Review

9 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q4 2022, worth a combined $377K — down 34% from $571K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ABVC and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, opening a new position worth an estimated $3.16K. The largest seller was Susquehanna International Group, cutting an estimated $13.5K.

  • 9 institutional investors held ABVC BioPharma (ABVC) as of Q4 2022, down from 11 in Q3 2022.
  • Funds reported $377K of ABVC BioPharma stock for Q4 2022, down 34% quarter-over-quarter.
  • 2 funds opened new ABVC BioPharma positions in Q4 2022 and 4 closed out, a net change of -2 holders.
  • The largest ABVC BioPharma buyer in Q4 2022 was UBS Group, an estimated $3.16K added.
  • The largest ABVC BioPharma seller in Q4 2022 was Susquehanna International Group, an estimated $13.5K sold.

Based on aggregated 13F filings for Q4 2022.